secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001193125-26-046536
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vikings Q4 net loss $157.7M; cash $706M; oral VK2735 Phase 3 to start 3Q26
--------------------------------------------------------------------------

- Full-year 2025 net loss $358.5M ($3.19/sh) vs $110.0M in 2024; R&D spend $345M (up 240% YoY).
- Cash & investments $706M at Dec 31, 2025 vs $903M a year earlier; burn reflects Phase 3 ramp.
- VANQUISH-1 (obesity) enrollment completed >4,500 ahead of schedule; VANQUISH-2 (obesity+diabetes) near full.
- Oral VK2735 to advance to Phase 3 in 3Q26 after FDA end-of-Phase 2 meeting; maintenance dosing data due 3Q26.
- IND filing for novel amylin agonist planned in 1Q26; Phase 1 maintenance study fully enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/0001193125-26-046536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-20260211.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-046536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer